Ondansetron Hydrochloride/Rizatriptan Benzoate

盐酸昂丹司琼/苯甲酸利扎曲普坦

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOndansetron Hydrochloride/Rizatriptan Benzoate
Drug Alias NameRizatriptan Benzoate/Ondansetron Hydrochloride苯甲酸利扎曲普坦/盐酸昂丹司琼Rizatriptan/ondansetronOndansetron/RizatriptanMSRX-202
ClassificationSmall molecules
Mechanisms of ActionSerotonin 1b (5-HT1b) receptor agonistsSerotonin 3 (5-HT3) receptor antagonistsSerotonin 1d (5-HT1d) receptor agonists
TargetsSerotonin 1b (5-HT1b) receptorSerotonin 3 (5-HT3) receptorSerotonin 1d (5-HT1d) receptor
Therapy Area/IndicationsNauseaMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Ondansetron HydrochlorideRizatriptan Benzoate
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAquestive Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAquestive Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsNauseaMigraine Disorders

Other Information

ATC CodeN/A
Related LinksN/A